RX871024
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
RX871024 is an experimental drug containing an imidazoline moiety, developed by Reckitt Benckiser. The development of RX871024 was discontinued in 1997. It is known for its potent ability to enhance insulin action. RX871024 stimulates insulin secretion from pancreatic beta cells through multiple mechanisms.
RX871024 is an experimental drug containing an imidazoline moiety, developed by Reckitt Benckiser. The development of RX871024 was discontinued in 1997. It is known for its potent ability to enhance insulin action. RX871024 stimulates insulin secretion from pancreatic beta cells through multiple mechanisms.
Synthesis
Ex 1: The reaction between ethyl 1-phenyl-1H-indole-2-carboxylate [20538-24-3] (1) and ethylenediamine (2) gives RX871024 (3). Prec: Patent: Also, reaction of 1-phenylindole-2-carbonitrile, PC20095505 with ethylenediamine monotosylate [14034-59-4] gives higher yield.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1330110853 under CC BY-SA 4.0; modifications have been made.